Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Research and development services and license fees

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept mnlk:AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's research and development services and license fees.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's research and development services and license fees?
MoonLake Immunotherapeutics (MLTX) reported research and development services and license fees of $8.68M in Q1 2026.
How has MoonLake Immunotherapeutics's research and development services and license fees changed year-over-year?
MoonLake Immunotherapeutics's research and development services and license fees increased by 113.3% year-over-year, from $4.07M to $8.68M.
What is the long-term trend for MoonLake Immunotherapeutics's research and development services and license fees?
Over 2 years (2023 to 2025), MoonLake Immunotherapeutics's research and development services and license fees has grown at a 85.6% compound annual growth rate (CAGR), from $1.23M to $4.23M.